F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2) agonists. As such, they are believed to ...
Filing acceptance based on phase III ALLEGORY data for Gazyva/Gazyvaro showing a significant reduction in disease activity compared with placebo in people with systemic lupus erythematosus (SLE)If app ...
Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple scleros ...
DUBLIN--(BUSINESS WIRE)--The "Enterprise Tech Ecosystem Series: F. Hoffmann - La Roche Ltd 2024" report has been added to ResearchAndMarkets.com's offering. The report provides insights into company's ...
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described imidazo[4,5-b]pyridine and pyrazolo[1,5-a]pyrimidine derivatives acting as serine/threonine-protein kinase SIK ...
Due to unsubstantiated, frivolous claims by Swiss drug-maker F. Hoffmann-La Roche, Ltd. in a desperate attempt to cease the distribution of the Russian-made anti-tumour biosimilar products, as well as ...
Article ‘Count’ and ‘Share’ for Hoffmann-La Roche Ltd. based on listed parameters only. The articles listed below published by authors from Hoffmann-La Roche Ltd., organized by journal and article, ...